Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab176053-100μg
|
100μg |
10
|
$59.90
|
|
|
Ab176053-1mg
|
1mg |
4
|
$289.90
|
|
|
Ab176053-5mg
|
5mg |
1
|
$749.90
|
|
|
Ab176053-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,189.90
|
|
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Icrucumab (anti-FLT1) - Primary antibody, specific to FLT1, >95%, high purity, Human IgG1, ANTAGONIST of Vascular endothelial growth factor receptor 1 antagonist |
|---|---|
| Synonyms | EC 2.7.10.1 | FLT | FLT-1 | Fms-like tyrosine kinase 1 | Tyrosine-protein kinase FRT | Tyrosine-protein kinase receptor FLT | Vascular permeability factor receptor | VEGFR-1 |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | FLT1 |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | ANTAGONIST |
| Mechanism of action | ANTAGONIST of Vascular endothelial growth factor receptor 1 antagonist |
| Product Description |
Icrucumab (anti-FLT1) is a humanized Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab (anti-FLT1) has the potential for the research of advanced solid tumors. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 146.8kDa |
| Purification Method | Protein A purified |
| Purity | >95% |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 1024603-92-6 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Icrucumab (anti-FLT1) (Ab176053) - ELISA
Immobilized Human VEGFR1/FLT1-his is at 2.0 μg/mL can bind Icrucumab (anti-FLT1) (Ab176053) with the EC₅₀ of 15.19 ng/mL.
Icrucumab (anti-FLT1) (Ab176053) - SEC
The purity of Icrucumab (anti-FLT1) (Ab176053) is more than 95% verified by HPLC.
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Apr 08, 2024 | Ab176053 | |
| Certificate of Analysis | Apr 08, 2024 | Ab176053 | |
| Certificate of Analysis | Apr 08, 2024 | Ab176053 |
Starting at $66.90
Starting at $66.90